How Leptin Raises Blood Pressure Through Neuropeptide Y and Melanocortin Signaling in the Brain

Researchers used anesthetized male Sprague-Dawley rats and delivered leptin via intracerebroventricular injection. They measured lumbar sympathetic nerve activity, heart rate, and mean arterial pressure. To dissect the neural circuitry, they systematically injected pharmacological blockers into the paraventricular nucleus — muscimol (general inhibitor), SHU9119 (melanocortin 3/4 receptor blocker), kynurenate (glutamate receptor blocker), and neuropeptide Y Y1 receptor antagonist — alone and in combination, to determine each pathway's contribution.

Obesity-related hypertension is a major health problem, and elevated leptin levels in obese individuals may directly contribute to high blood pressure through sympathetic activation. Understanding the specific neuropeptide pathways — especially that neuropeptide Y withdrawal is required for melanocortin-driven blood pressure increases — could reveal new drug targets for treating hypertension in obese patients without affecting other leptin functions.

This study connects three major neuropeptide systems — leptin signaling, the melanocortin system (α-MSH), and neuropeptide Y — in a single circuit controlling blood pressure. It helps explain why obesity, which raises leptin levels, so commonly leads to hypertension. The finding that neuropeptide Y acts as a gating mechanism for melanocortin-driven sympathetic activation adds an important layer of complexity to our understanding of hypothalamic control of cardiovascular function.

The study was conducted in anesthetized rats, and anesthesia can alter neural signaling and cardiovascular reflexes. The findings may not directly translate to awake animals or humans. Intracerebroventricular leptin delivery produces brain-wide exposure rather than targeting specific nuclei. Sample sizes for individual experimental groups are not reported in the abstract. Only male rats were studied.